4113.T

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 1.96, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes a medium liquidity risk, as net cash is negative after subtracting total debt. The company's price-to-book ratio of 0.57 and price-to-tangible-book ratio of 0.57 suggest that the market values the company's equity at a discount relative to its book value.

Profitability metrics show a return on equity (ROE) of 7.99% and a return on assets (ROA) of 4.86%, which are below the industry's preferred metrics for high-performing chemical firms. The company's gross profit margin is 18.35% (5,491,000,000 JPY / 29,930,000,000 JPY), and its operating margin is 6.30% (1,886,000,000 JPY / 29,930,000,000 JPY), both of which are below the median for the Diversified Chemicals industry.

The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of revenue across different markets or product lines. However, the lack of detailed segment reporting may indicate a broad but undifferentiated exposure to the global chemical market.

The company's growth trajectory appears to be modest, with no specific numeric deltas provided for the current or next fiscal year. Analysts have estimated a mean revenue of 36,500,000,000 JPY for the upcoming period, compared to the actual revenue of 29,930,000,000 JPY in the most recent period, suggesting a potential growth rate of approximately 21.95%. However, the company's earnings per share (EPS) have shown a slight decline, with the last actual EPS at 103.18 JPY compared to the mean estimate of 94.20 JPY.

The risk assessment highlights a low dilution risk, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure remains stable, with no recent dilutive events reported. The risk assessment also notes a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt.

Recent events and filings do not provide specific details on the company's operations or strategic initiatives. However, the company's financial performance and market valuation suggest a stable but unremarkable position in the Diversified Chemicals industry. The company's price-to-earnings ratio of 7.17 and enterprise value-to-EBITDA ratio of 5.97 indicate a relatively low valuation compared to industry peers.